MuSK-CAART: A novel precision cellular therapy for muscle-specific tyrosine kinase myasthenia gravis

Precision cellular therapy for MuSK myasthenia gravis

Authors

DOI:

https://doi.org/10.17161/rrnmf.v4i3.19417

Keywords:

autoimmunity, neurology, immunotherapy, CAR T cells, neuromuscular junction

Abstract

Chimeric autoantibody receptor (CAAR) T cells are a novel genetically-engineered T cell immunotherapy that aims to durably eliminate antigen-specific B cells while sparing healthy B cells, ideally leading to safe and lasting remission of B cell-mediated autoimmune diseases with a one-time infusion. We describe the preclinical development of muscle-specific tyrosine kinase CAAR T cells (MuSK-CAART) for the treatment of MuSK myasthenia gravis, a debilitating autoantibody-mediated disease that causes potentially life-threatening muscle weakness.

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.

Author Biography

  • Sangwook Oh, University of Pennsylvania

    Senior Research Investigator, Department of Dermatology, University of Pennsylvania

Downloads

Published

2023-08-29

Issue

Vol. 4 No. 3 (2023): Proceedings of the MGFA International Conference

Section

MGFA International Conference Proceedings

License

Copyright (c) 2023 Aimee Payne, Sangwook Oh

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Payne, A., & Oh, S. (2023). MuSK-CAART: A novel precision cellular therapy for muscle-specific tyrosine kinase myasthenia gravis : Precision cellular therapy for MuSK myasthenia gravis. RRNMF Neuromuscular Journal, 4(3). https://doi.org/10.17161/rrnmf.v4i3.19417